A 29-year-old male patient with a history of neurofibromatosis type II and bilateral vestibular schwannomas was referred for evaluation of new-onset proteinuria. The patient’s schwannomas were inoperable, and he was treated with bevacizumab 10mg/kg intravenously every 3 weeks. After 18 months of therapy, serial imaging showed stabilization of the schwannoma size and sequential monitoring of urine analyses showed new-onset proteinuria without changes in kidney function. Bevacizumab was discontinued and he was referred for nephrology evaluation.